One pioneering approach, discussed in a review article published this week in WIRE’s Nanomedicine and Nanobiotechnology, uses nanoparticles to jumpstart the body’s ability to fight tumors. Nanoparticles are too small to imagine. …
“Right now, we don’t know who, we don’t know when, and we don’t know why people develop brain tumors,” said Elizabeth M. Wilson, MNA, President and CEO, American Brain Tumor Association. “It’s frustrating for the brain tumor community, and it’s why the American Brain Tumor Association funds research to pursue answers to these questions, and it’s why we host this national conference to provide answers families desperately seek.” At the American Brain Tumor Association (ABTA) annual Patient and Family Conference in Chicago, July 25-26, Jill Barnholtz-Sloan, PhD, Associate Professor, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, will be the keynote speaker and provide an update on possible causes and risk factors for brain tumors. As Dr. …
Activation of the PI3K/AKT signal pathway is a known driver of the progression of prostate cancer to the castrate-resistant stage, the most lethal form of prostate cancer. Using a genome-wide genetic screen, Dr. Gelman and colleagues identified a previously unknown metastasis suppressor — the FOXO4 protein, which belongs to a family of genes that are produced by all human cells. …
The findings, published in JAMA Internal Medicine, sought to examine why active surveillance, a management program for low-risk disease, which includes repeat PSAs, prostate exams and biopsies, is underused in this patient population. According to the American Cancer Society, 233,000 new cases of prostate cancer will be diagnosed this year, making it the most common non-skin cancer in men…
However, a new Cincinnati Cancer Center (CCC) study, published in the advance online edition of the journal Oncotarget, provides hope that previously studied SapC-DOPS could be used for treatment of brain cancer that has spread. Xiaoyang Qi, PhD, member of the CCC, associate director and associate professor in the division of hematology oncology at the University of Cincinnati (UC) College of Medicine and a member of the UC Cancer and Neuroscience Institutes and the Brain Tumor Center, says this critical data shows promise for finding treatment for one of the deadliest cancers. A lysosomal protein saposin C (SapC), and a phospholipid, known as dioleoylphosphatidylserine (DOPS), can be combined and assembled into tiny cavities, or nanovesicles, to target and kill many forms of cancer cells…
During the study, 36 patients with muscle-invasive bladder cancer received chemotherapy before surgery, consisting of an accelerated regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). By the time surgery rolled around, 14 patients appeared cancer-free. All but one of these patients carried mutations in at least one of three specific genes; none of these mutations were present in any of the people who still harbored traces of cancer after AMVAC. …
The work by Professor Pierre Sonveaux’s team, at Université catholique de Louvain’s Institute of Experimental and Clinical Research (IREC), succeeded in pinpointing a family of pharmaceutical compounds whose action prevents the appearance of tumor metastasis. The researchers achieved this tour de force by studying the mitochondria in tumor cells. These organelles are considered as the cells’ power station…
source : http://www.sciencedaily.com/releases/2014/07/140721123743.htm
source : http://www.sciencedaily.com/releases/2014/07/140716090732.htm
source : http://www.sciencedaily.com/releases/2014/07/140717212144.htm